

**OVERALL CERTIFICATE  
FOR FINANCIAL STATEMENTS  
COMPANIES ACT 2014**

**GOOD PHARMA DERMATOLOGY LIMITED**

**COMPANY NO. 572718**

**ABRIDGED ACCOUNTS FOR THE  
YEAR ENDED 31 MARCH 2025**

**CERTIFICATE:**


**WE HEREBY CERTIFY** that all documents which are required under Part 6 of the Companies Act 2014 to be annexed to this return, have been so annexed, and that they are true copies of the originals laid or to be laid before the relevant general meeting, or presented to the members.



**Secretary**

**JOHN O'SHEA**

**28 January 2026**



**Director**

**JASON HUMPHRIES**

**Company registration number: 572718**

**Good Pharma Dermatology Limited**  
**Unaudited abridged financial statements**  
**for the financial year ended 31 March 2025**

**Good Pharma Dermatology Limited**

**Contents**

	<b>Page</b>
Directors responsibilities statement	<b>1</b>
Balance sheet	<b>2 - 3</b>
Notes to the financial statements	<b>4</b>

## **Good Pharma Dermatology Limited**

### **Directors responsibilities statement**

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

Company law requires the directors to prepare financial statements for each financial year. Under that law, they have elected to prepare the financial statements in accordance with FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime (FRS 105).

As such the directors are responsible for preparing financial statements in accordance with the provisions of the Companies Act 2014 with which the company is obliged to comply, including the appropriate use of the going concern basis of accounting, which is consistent with those requirements, and having availed of the exemptions to which the company is entitled by virtue of qualifying for the micro companies regime and FRS 105. Thereby, the financial statements are presumed, in law, to give a true and fair view without any consideration of any other circumstances, factors, accounting principles or disclosures.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the company and enable them to ensure that the financial statements comply with the Companies Act 2014. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities.

**Good Pharma Dermatology Limited**

**Balance sheet  
As at 31 March 2025**

	2025		2024	
	€	€	€	€
Current assets	152,386		48,556	
Prepayments and accrued income	564		-	
	<u>152,950</u>	/	<u>48,556</u>	
Creditors: amounts falling due within one year	(117,304)		(117,785)	
<b>Net current assets/(liabilities)</b>	<u>35,646</u>		<u>(69,229)</u>	
<b>Total assets less current liabilities</b>	35,646		(69,229)	
Accruals and deferred income	(1,723)		(4,144)	
<b>Net assets/(liabilities)</b>	<u>33,923</u>		<u>(73,373)</u>	
<b>Capital and reserves</b>	<u>33,923</u>		<u>(73,373)</u>	

We, as directors of Good Pharma Dermatology Limited state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- (c) the shareholder of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- (e) the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a micro company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements have been prepared in accordance with the micro companies regime.


**Good Pharma Dermatology Limited**

**Balance sheet (continued)  
As at 31 March 2025**

These abridged financial statements were approved by the board of directors on 28 January 2026 and signed on behalf of the board by:



**John O'Shea**  
Director



**Jason Humphries**  
Director

Company registration number: 572718

**Good Pharma Dermatology Limited**

**Notes to the abridged financial statements  
Financial year ended 31 March 2025**

**1. General information**

The company is a private company limited by shares, registered in Ireland. The address of the registered office is Klima House, 2 Brookfield Avenue, Blackrock, Co. Dublin.

**2. Statement of compliance**

These financial statements have been prepared in accordance with FRS 105, 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

**3. Accounting policies and measurement bases**

**Basis of preparation**

The financial statements have been prepared on the historical cost basis.

The financial statements are prepared in Euro, which is the functional currency of the entity.

**Turnover**

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

**Taxation**

Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Tax is recognised on taxable profit for the current and past periods. Tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

**Stocks**

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

**4. Appropriations of profit and loss account**

	2025	2024
	€	€
At the start of the financial year	(73,373)	(144,309)
Profit for the financial year	107,295	70,935
<b>At the end of the financial year</b>	<u>33,922</u>	<u>(73,374)</u>